A. baumannii infection VAP, implicated in 3-7% of cases, leading to an increased mortality rate. Acinetobacter baumannii HAP/VAP, carbapenem-resistant, multidrug-resistant, sitafloxacin
Conditions
Interventions
The participants were randomly assigned to receive a loading dose of 300 mg colistin, followed by 150 mg every 12 hours in combination with a high dose of meropenem, 2 g every 8 hours with 3-hour exte
Experimental Drug,Experimental Drug
sitafloxacin-colistin-meropenem ,colistin-meropenem
Sponsors
Rajavithi Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: patients aged over 18 years who were diagnosed with CRAB HAP/VAP.
Exclusion criteria
Exclusion criteria: 1.Sputum culture: colistin-resistant A. baumannii strains 2.Other organ sites of A. baumannii infection 3.Acute kidney injury or chronic kidney disease stage 3 or above 4.Liver failure 5.History of fluoroquinolone allergy 6.Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mortality 7, 14-day after treatment mortality rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical response 3, 7-day after treatment symptoms and signs (defervescence, decreasing FiO2, successful mechanical ventilator weaning), laboratory values, and organ function markers (e.g., APACHE II score, qSOFA score) | — |
Countries
Thailand
Contacts
Public ContactRajavithi Hospital
Rajavithi hospital
Outcome results
None listed